AT-7519

N/A

Report date: 2025/10/09 20:00:09
NME

Base Information

Drug NameAT-7519
Drug Alias NameAT-7519AT-7519M
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 9 inhibitorsCyclin-dependent kinase 2 inhibitorsCyclin-dependent kinase 1 inhibitors +[5] 
TargetsCyclin-dependent kinase 1Cyclin-dependent kinase 9Cyclin-dependent kinase 2 +[5] 
Therapy Area/IndicationsSolid tumoursMultiple MyelomaLymphoma, Mantle-Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstex Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma AgNational Cancer InstituteAstex Pharmaceuticals Inc +[4] 
Active IndicationsN/A
Inactive IndicationsSolid tumoursMultiple MyelomaLymphoma, Mantle-Cell +[5] 

Other Information

ATC CodeN/A
Related LinksDrugBank